Prostemics Co. Ltd (203690) - Net Assets

Latest as of March 2026: ₩24.87 Billion KRW ≈ $16.85 Million USD

Based on the latest financial reports, Prostemics Co. Ltd (203690) has net assets worth ₩24.87 Billion KRW (≈ $16.85 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩39.70 Billion ≈ $26.91 Million USD) and total liabilities (₩14.84 Billion ≈ $10.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Prostemics Co. Ltd for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩24.87 Billion
% of Total Assets	62.63%
Annual Growth Rate	-4.08%
5-Year Change	86.39%
10-Year Change	-42.12%
Growth Volatility	68.63

Prostemics Co. Ltd - Net Assets Trend (2015–2025)

This chart illustrates how Prostemics Co. Ltd's net assets have evolved over time, based on quarterly financial data. Check Prostemics Co. Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Prostemics Co. Ltd (2015–2025)

The table below shows the annual net assets of Prostemics Co. Ltd from 2015 to 2025. For live valuation and market cap data, see 203690 stock market capitalisation.

Year	Net Assets	Change
2025-12-31	₩25.96 Billion ≈ $17.59 Million	+0.07%
2024-12-31	₩25.94 Billion ≈ $17.58 Million	-14.75%
2023-12-31	₩30.43 Billion ≈ $20.62 Million	+209.69%
2022-12-31	₩9.83 Billion ≈ $6.66 Million	-29.45%
2021-12-31	₩13.93 Billion ≈ $9.44 Million	-35.13%
2020-12-31	₩21.47 Billion ≈ $14.55 Million	-24.27%
2019-12-31	₩28.35 Billion ≈ $19.21 Million	-11.08%
2018-12-31	₩31.89 Billion ≈ $21.61 Million	-18.56%
2017-12-31	₩39.16 Billion ≈ $26.54 Million	-12.71%
2016-12-31	₩44.86 Billion ≈ $30.40 Million	+13.91%
2015-12-31	₩39.38 Billion ≈ $26.69 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Prostemics Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 550935250000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Other Components	₩41.40 Billion	159.45%
Total Equity	₩25.96 Billion	100.00%

Prostemics Co. Ltd Competitors by Market Cap

The table below lists competitors of Prostemics Co. Ltd ranked by their market capitalization.

Company	Market Cap
BT Wealth Industries Public Company Limited BK:BTW	$1.89 Million
KINGS ENTERTAINMENT GROUP F:L12	$1.89 Million
Astron Paper & Board Mill Limited NSE:ASTRON	$1.89 Million
Filament Health Corp NEO:FH	$1.89 Million
MJ Gleeson plc LSE:GLE	$1.88 Million
ETRUSCUS RESOURCES CORP. F:ERR	$1.88 Million
Nexera Energy Inc V:NGY	$1.88 Million
Rainbow Rare Earths Limited LSE:RBW	$1.87 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Prostemics Co. Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 25,943,463,000 to 25,961,949,000, a change of 18,486,000 (0.1%).
Net loss of 11,795,421,530 reduced equity.
New share issuances of 7,601,998,590 increased equity.
Other factors increased equity by 4,211,908,940.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩-11.80 Billion	-45.43%
Share Issuances	₩7.60 Billion	+29.28%
Other Changes	₩4.21 Billion	+16.22%
Total Change	₩-	0.07%

Book Value vs Market Value Analysis

This analysis compares Prostemics Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.11x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩993.15	₩139.00	x
2017-12-31	₩883.04	₩139.00	x
2018-12-31	₩715.74	₩139.00	x
2019-12-31	₩632.13	₩139.00	x
2020-12-31	₩477.88	₩139.00	x
2021-12-31	₩309.98	₩139.00	x
2022-12-31	₩217.97	₩139.00	x
2023-12-31	₩2738.73	₩139.00	x
2024-12-31	₩1776.08	₩139.00	x
2025-12-31	₩1298.77	₩139.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Prostemics Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -45.43%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -73.36%
• Asset Turnover: 0.38x
• Equity Multiplier: 1.64x
Recent ROE (-45.43%) is below the historical average (-32.26%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2015	-21.63%	-57.41%	0.34x	1.10x	₩-12.45 Billion
2016	9.62%	30.45%	0.30x	1.05x	₩-172.64 Million
2017	-8.06%	-48.10%	0.16x	1.04x	₩-7.07 Billion
2018	-19.75%	-133.46%	0.14x	1.04x	₩-9.49 Billion
2019	-11.23%	-44.66%	0.22x	1.12x	₩-6.02 Billion
2020	-33.83%	-35.05%	0.34x	2.80x	₩-9.41 Billion
2021	-51.99%	-22.26%	0.61x	3.82x	₩-8.63 Billion
2022	-56.59%	-20.92%	0.52x	5.24x	₩-6.54 Billion
2023	-79.65%	-65.07%	0.48x	2.54x	₩-27.28 Billion
2024	-36.33%	-28.37%	0.54x	2.35x	₩-12.02 Billion
2025	-45.43%	-73.36%	0.38x	1.64x	₩-14.39 Billion

Industry Comparison

This section compares Prostemics Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $279,963,614,530
Average return on equity (ROE) among peers: -2.04%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Prostemics Co. Ltd (203690)	₩24.87 Billion	-21.63%	0.60x	$1.88 Million
ORIENTBIO Inc. (002630)	$48.55 Billion	-31.47%	0.47x	$68.31 Million
Green Cross (005250)	$522.78 Billion	7.15%	5.40x	$298.12 Million
Green Cross Holdings Preference Shares (005257)	$1.85 Trillion	1.30%	0.98x	$2.77 Million
Pharmicell (005690)	$80.40 Billion	4.45%	0.15x	$463.57 Million
GeneOne Life Science Inc (011000)	$98.51 Billion	-18.93%	0.39x	$32.81 Million
HLB Co. Ltd (028300)	$19.38 Billion	0.00%	1.48x	$2.31 Billion
Mgenplus Co. Ltd. (032790)	$18.79 Billion	0.00%	1.65x	$15.75 Million
Daesung Microbiological Labs. Co. Ltd (036480)	$37.00 Billion	2.34%	0.69x	$15.89 Million
Seoulin Bioscience Co.Ltd (038070)	$53.72 Billion	4.89%	0.32x	$26.32 Million
Hyundai Bioscience Co. Ltd (048410)	$68.34 Billion	9.92%	2.55x	$452.33 Million

About Prostemics Co. Ltd

KQ:203690 Korea Biotechnology

Market Cap

$1.88 Million

₩2.78 Billion KRW

Market Cap Rank

#30084 Global

#2100 in Korea

Share Price

₩139.00

Change (1 day)

+0.00%

52-Week Range

₩139.00 - ₩139.00

All Time High

₩77250.00